NDAVAGINALOINTMENT
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VAGISTAT-1 (tioconazole) is a vaginal antifungal ointment approved in 1997 for the treatment of vaginal yeast infections. It is a small-molecule azole that disrupts fungal cell membrane integrity by inhibiting lanosterol demethylase. This is a mature, over-the-counter product for symptomatic women with vulvovaginal candidiasis.
LOE Approaching
LOE-stage product with moderate competitive pressure (30 rating) suggests a defensive commercial posture with limited growth opportunities for brand expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VAGISTAT-1 offers limited career growth in a LOE-stage, low-linked-job product with minimal brand visibility. Roles are primarily operational and defensive, focused on cost containment and regulatory compliance rather than strategic innovation.
Brand ManagerField Sales Representative
Worked on VAGISTAT-1 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.